Bronchogen
Research OnlyA synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide · Respiratory peptide
Preclinical evidence only
- Preclinical
- 67%
- Human research
- 0%
Based on 12 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
The proposed mechanisms of Bronchogen are based entirely on Russian bioregulator research from the St. Petersburg Institute of Bioregulation and Gerontology. No independent Western validation exists for any claimed mechanisms.
How It Works (Simplified)
Bronchogen is claimed to target bronchial tissue through gene expression modulation:
Claimed to selectively bind bronchial tissue DNA sequences and modulate gene expression patterns relevant to respiratory function.
Proposed to stimulate bronchial mucosal regeneration and support repair of respiratory epithelium, particularly in aged tissue.
Claimed to modulate cytokine profiles and immune responses within respiratory mucosa for improved local defense.
Part of Khavinson’s bioregulator theory that short peptides can selectively target specific tissue types through sequence-specific DNA binding.
Note: These pathways are based on Russian bioregulator theory and have not been independently validated by Western research.
Important Limitations
- 100% of research from single institute (St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication of any claimed effects
- No controlled human clinical trials with placebo comparison
- Pharmacokinetics, bioavailability, and optimal dosing completely uncharacterized
- Mechanism of tissue-specific targeting is theoretical and unvalidated
- Claims of gene expression modulation lack rigorous molecular characterization
- Translation from Russian observational studies to therapeutic benefit is unconfirmed
Based on Russian protocols: Initial effects on bronchial tissue gene expression may begin. Cell culture studies suggest peptide-DNA interactions occur within days. No validated human pharmacokinetic data.
PMID:25015171Russian protocols typically involve treatment courses of 10-20 days. Claimed effects on bronchial mucosal regeneration may develop. Immune modulation in respiratory tract suggested.
PMID:26468022Extended treatment in Russian studies shows claimed improvements in respiratory function markers. Tissue regeneration effects reported in animal models. Human response timelines are speculative.
PMID:30199201Long-term effects based on Russian observational studies in elderly populations. Cyclical treatment protocols often recommended (treatment courses with rest periods). Optimal duration unknown.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct tissue targets - epithalon for pineal/longevity, bronchogen for bronchial epithelium. No known direct interactions.
Thymalin
CompatibleThymalin targets thymic immune function while bronchogen targets respiratory epithelium. May have complementary effects for respiratory immune support.
Vilon
CompatibleBoth short Russian bioregulator peptides - vilon for immune modulation, bronchogen for bronchial tissue. Different tissue targets with no known contraindications.
Thymosin-Alpha-1
CompatibleTa1 provides broad immune modulation while bronchogen targets bronchial tissue specifically. May complement each other for respiratory health.
BPC-157
CompatibleBPC-157 provides systemic tissue healing while bronchogen targets bronchial epithelium specifically. No known contraindications in combination.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Bronchogen
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
BT5528
Bicycle Toxin Conjugate 5528 · EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.
Cardiogen
AED · Ala-Glu-Asp · Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.
Chelohart
Heart cytamin · Cardiac peptide supplement · A-14 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01 · Evaxion EVX-01
EVX-01 is an investigational, patient-specific neoantigen peptide vaccine studied with anti-PD-1 therapy in advanced melanoma. Two small single-arm cohorts show vaccine-specific T-cell responses and observed tumor responses, but they cannot establish how much EVX-01 adds to checkpoint treatment.
Compared With
3 comparisonsConditions Studied
3 entries- Bronchogen for Chronic Bronchitis Bronchogen was developed specifically for bronchial conditions. Russian animal studies report reversal of bronchial epithelium rem…
- Bronchogen for Respiratory Aging Russian research suggests bronchogen may address age-related decline in bronchial tissue function. Organotypic culture studies rep…
- Bronchogen for Chronic Obstructive Pulmonary Disease Some Russian studies have examined bronchogen in rat models of chronic obstructive pulmonary disease. Evidence is extremely limite…